As part of a joint Phase I trial of an experimental AIDS vaccine, Dutch biopharmaceutical company Crucell NV and Harvard will enroll HIV-free adults in the United States and Africa to test a vaccine combining two adenovirus-based vaccines.
As part of a joint Phase I trial of an experimental AIDS vaccine, Dutch biopharmaceutical company Crucell NV and Harvard will enroll HIV-free adults in the United States and Africa to test a vaccine combining two adenovirus-based vaccines.
Researchers with the Oslo University and Bionor Immuno at the XVIII International AIDS Conference in Vienna, Austria, recently released the results of a re-vaccination study of Norway’s largest hospital using the company's furthest advance HIV vaccine can
According to a new study released on July 22, smallpox inoculation may offer some protection against primary HIV infection.
Officials with the Finnish pharmaceutical company Fit Biotech announced recently that results of an HIV vaccination they have been developing are promising.
Officials with the AIDS Research Consortium of Atlanta recently called for volunteers to test a DNA-based AIDS vaccine by GeoVax.
The discontinuation of the smallpox vaccine may have been a factor in the spread of AIDS , according to the results of a study recently published in BMC Immunology.
Researchers report that they've gained more insight into how the body fights off HIV, a finding that offers a possible new avenue toward a vaccine against the virus, which causes AIDS.
Peregrine Pharmaceuticals Inc. announced April 5 the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells.
OTTAWA — Canada has pulled the plug on funding to one of the largest AIDS vaccine development agencies in the world, the Winnipeg Free Press reported March 31.
There is relatively little interest about tuberculosis in the United States because there is a perception that this is just a developing world issue, says Tevi Troy, a writer and consultant on health care and domestic policy
On March 24, Aeras Global TB Vaccine Foundation recommitted itself to developing new and better TB vaccines and observed World TB Day 2010 by participating in events on three continents, the group said in a press release.
Approximately 1 in 6 Americans (16.2 percent) between the ages of 14 and 49 is infected with herpes simplex virus type 2, according to a national health survey released March 9 by the Centers for Disease Control and Prevention.
LEIDEN, Netherlands — Dutch biopharmaceutical company Crucell announced March 8 that Jerald C. Sadoff was appointed chief medical officer will be a member of its management committee.
A seven-valent pneumococcal conjugate vaccine can protect adults with HIV against recurrent pneumococcal infection, according to research published in the March 4 issue of the New England Journal of Medicine.
Cyto Pulse Sciences announced approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet and the Swedish Institute for Infectious Disease Control.
For the first time researchers from the U.S. and abroad have shown that a single-dose HIV DNA vaccine can induce a long-lasting HIV-specific immune response in nonhuman primates.
The head of an association that represents Canada's HIV researchers is criticizing a federal government decision to scrap plans for an $83.5 million facility that would manufacture potential vaccines.
AltraVax Inc. has acquired a vaccine development technology package that gives AltraVax an exclusive license to develop vaccines for infectious diseases and is targeting influenza, a treatment for hepatitis B and HIV.
WASHINGTON — A company using genetically engineered versions of the AIDS virus says its unusual approach is getting some results, both for treating and perhaps as a vaccine against HIV.
WASHINGTON — An AIDS vaccine that appears to have worked at least partly in Thailand may only temporarily protect patients, with the effects starting to wane after a year or so, researchers reported Feb. 18.
ATLANTA — GeoVax Labs, a biopharmaceutical company that develops vaccines for diseases caused by HIV and other infectious agents, announced the appointment of a vice president of research and development.
PHILADELPHIA — Researchers from Thomas Jefferson University are one step closer to developing a vaccine against AIDS, the school announced Dec. 14.
Researchers have identified the cause of a major hurdle in efforts to develop an AIDS vaccine, according to a report Dec. 18 in HealthDay News.
Kampala, Uganda — Fewer women compared to men are willing to participate in trials for a potential HIV/Aids vaccine, researchers revealed Dec. 15.
Researchers have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.
HIV-infected adults are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine, the National Institutes of Health announced Dec. 10.
WASHINGTON, D.C. — America’s pharmaceutical research and biotechnology companies are testing 97 medicines and vaccines to treat or prevent HIV/AIDS and related conditions.
KVISTGARD, Denmark — Bavarian Nordic A/S announced Nov. 30 that it expects to file a new drug submission for its third-generation smallpox vaccine, Imvamune with Health Canada in the second half of 2010.
BRAZZAVILLE, Republic of Congo — An unknown epidemic caused three deaths and affected more than 100 people in the last few days in the Republic of Congo.
World AIDS Day on Dec. 1 is intended to draw together people from around the world to raise awareness about HIV/AIDS and demonstrate international solidarity in the face of the pandemic, according to the World Health Organization.
GENEVA and SHANGHAI — According to new data in the 2009 AIDS epidemic update, new HIV infections have been reduced by 17 percent over the past eight years, the World Health Organization and United Nations Program on HIV/AIDS announced Nov. 24.
Dr. Anthony Fauci wrote this commentary, posted Nov. 17, for msnbc.com. He is director of the National Institute of Allergy and Infectious Diseases in Bethesda, Md.
The recent failure of an HIV vaccine was probably caused by the immune system reacting to the virus “shell” used to transmit the therapy around the body, according to research published Nov. 16 in the Proceedings of the National Academy of Sciences.
CHICAGO — Former President Bill Clinton says he believes there's going to be a vaccine for AIDS found before anyone discovers a cure for the disease, WBBM Radio reported.
A study of how the most robust antibodies work to block HIV as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine, ScienceDaily reported Nov. 10.
Brief electric shocks may help the body better respond to certain kinds of experimental AIDS vaccines, U.S. researchers said Oct. 22.
The priority for AIDS virologists in coming months, a leading researcher said, is to find out exactly how the Thailand vaccine, which gave 30 percent protection against HIV, worked.